Alpha Tau Medical (DRTSW) Liabilities and Shareholders Equity (2020 - 2026)
Alpha Tau Medical (DRTSW) posted Liabilities and Shareholders Equity of $108.8 million for Q1 2026, up 2.95% sequentially from $105.7 million in Q4 2025, and up 34.41% YoY from $80.9 million in Q1 2025.
Alpha Tau Medical (DRTSW) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Alpha Tau Medical has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $108.8 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 34.41% year-over-year to $108.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $430.1 million (up 21.52% YoY) and the FY2025 annual result came in at $105.7 million, up 22.56% from the prior year.
- Liabilities and Shareholders Equity grew to $108.8 million in Q1 2026 per DRTSW's latest filing, from $105.7 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $124.0 million in Q2 2022 and troughed at $80.9 million in Q1 2025.
- A 5-year average of $106.5 million and a median of $107.4 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 184.61% in 2022, then retreated 21.0% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $120.1 million in 2022, then decreased by 10.62% to $107.4 million in 2023, then decreased by 19.73% to $86.2 million in 2024, then advanced by 22.56% to $105.7 million in 2025, then gained by 2.95% to $108.8 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $108.8 million, $105.7 million, and $104.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Alpha Tau Medical | 383.00 Mn | 200.58 Mn | - | 134.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 134.25 Mn |
| Mar 31, 2026 | 108.77 Mn |
| Dec 31, 2025 | 105.65 Mn |
| Sep 30, 2025 | 104.69 Mn |
| Jun 30, 2025 | 110.95 Mn |
| Mar 31, 2025 | 80.93 Mn |
| Dec 31, 2024 | 86.20 Mn |
| Sep 30, 2024 | 90.73 Mn |
| Jun 30, 2024 | 96.05 Mn |
| Mar 31, 2024 | 102.44 Mn |
| Dec 31, 2023 | 107.39 Mn |
| Sep 30, 2023 | 106.38 Mn |
| Jun 30, 2023 | 111.21 Mn |
| Mar 31, 2023 | 116.05 Mn |
| Dec 31, 2022 | 120.15 Mn |
| Sep 30, 2022 | 119.37 Mn |
| Jun 30, 2022 | 123.98 Mn |
| Mar 31, 2022 | 119.04 Mn |
| Dec 31, 2021 | 42.22 Mn |
| Dec 31, 2020 | 52.99 Mn |